CATX
Perspective Therapeutics Inc.
2.50$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -11.4% | +184.3% | +38.7% | +1.4% | -12.8% | -3.4% | -5.7% | -5.1% | -9.4% | +53.9% | -4.6% | |
| – | -22.4% | +1,017.8% | +56.3% | -8.2% | -14.4% | -6.7% | -9.2% | -8.9% | -16.9% | +85.6% | -12.3% | |
| – | -48.6% | +1,438.4% | +77.3% | -10.1% | -72.8% | -27.9% | -35.0% | -7.2% | +14.4% | +76.2% | -10.2% | |
| – | -48.6% | +1,855.5% | +62.1% | -8.5% | -15.3% | -6.7% | -9.5% | -9.1% | -16.9% | +87.2% | -12.6% | |
| – | -32.1% | -15.0% | -85.8% | +52.8% | +583.4% | -94.7% | +188.5% | -20.4% | +480.4% | -94.4% | +363.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -11.9% | +0.0% | +0.0% | +0.0% | -100.0% | – | – | – | – | – | – | |
| – | +0.7% | -0.7% | +0.0% | +0.0% | +0.0% | 0.0% | +0.0% | +0.0% | -20.0% | 0.0% | +0.0% | |
| – | +93.3% | +113.1% | -7.2% | +39.5% | -19.5% | -11.4% | +0.7% | +16.8% | +13.9% | +5.7% | +7.6% | |
| – | +93.0% | -7.4% | -26.8% | +165.2% | -35.2% | -30.4% | +2.4% | +58.8% | +39.1% | +9.8% | +16.1% | |
| – | -72.1% | +87.4% | +334.8% | +23.3% | +5.8% | +2.4% | -12.8% | -15.8% | -10.5% | +65.7% | +2.6% | |
| – | +78.7% | -12.8% | +1.7% | +256.0% | -52.6% | -15.6% | -19.3% | +83.7% | +58.4% | +29.1% | +11.1% | |
| – | -0.8% | -0.8% | -0.7% | -0.8% | -0.8% | -0.9% | -0.9% | -0.9% | -0.9% | -1.0% | -0.9% | |
| – | -23.9% | +205.8% | +48.3% | -3.7% | -11.5% | -2.1% | -6.7% | -8.8% | -14.5% | +67.8% | -6.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +137.6% | -57.9% | +76.5% | +42.7% | -97.0% | +3,212.8% | +0.1% | +5.1% | +0.1% | -0.7% | +0.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.